GTx, Inc. (GTXI) Reports Q4 Loss of $0.44/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. AXP
7. TMUS
8. SPY
9. CVS
10. UNH

Go back to GTx, Inc. (GTXI) Reports Q4 Loss of $0.44/Share

GTx Provides Corporate Update and Reports Fourth Quarter and Year-End 2016 Financial Results

March 15, 2017 7:00 AM EDT

-- Enobosarm demonstrated clinical benefit and met the primary efficacy endpoint for the 9 mg dose cohort in GTxs ongoing ER+/AR+ Phase 2 breast cancer trial --

-- Company expects to report preliminary results from its Phase 2 clinical trial of enobosarm to treat Stress Urinary Incontinence (SUI) in the third quarter of 2017 --

-- Company expects to begin an initial clinical study of a Selective Androgen Receptor Degrader (SARD) in men with castration-resistant prostate cancer in the second half of 2017 --

MEMPHIS, Tenn.--(BUSINESS WIRE)--... More